Expedition Therapeutics Raises $115 Million in Series B Funding
Expedition Therapeutics, a San Francisco-based biotechnology company, announced on August 5, 2026, that it has raised $115 million in a Series B funding round. The company focuses on developing innovative therapies to address unmet medical needs. The funding round was led by General Atlantic, with participation from several other prominent investors.
Investor Participation
In addition to General Atlantic, the Series B round attracted investments from RA Capital, Vivo Capital, Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma, Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners. This diverse group of investors underscores the confidence in Expedition Therapeutics' potential to make significant strides in the biotechnology sector.
Leadership and Vision
The company is led by Founder and Director Aline Hagerimana and President and CEO Yi Larson. Larson stated, "This funding will allow us to accelerate our clinical programs and expand our therapeutic offerings to better serve patients in need." This strategic direction highlights the company's commitment to advancing its research and development efforts.
Strategic Use of Funds
The newly secured funds are earmarked for advancing Expedition Therapeutics' clinical research programs. The company plans to enhance its therapeutic pipeline, which could involve expanding into new treatment areas or accelerating existing projects. While specific details on the expansion were not disclosed, the investment will likely support further research and potential commercialization of their therapies.
Location and Market Impact
Based in the heart of San Francisco, California, Expedition Therapeutics is well-positioned within one of the world's leading biotech hubs. The company's efforts to develop groundbreaking treatments align with the broader industry's push toward innovative medical solutions.
Expedition Therapeutics' latest funding round marks a significant milestone in its journey to impact the biotechnology landscape positively. With substantial backing from a mix of investors, the company is set to further its mission of addressing critical healthcare challenges.